U.S. Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2289-2293

  Axelson, Michael ^a   Liu, Ke ^a   Jiang, Xiaoping ^a   He, Kun ^a   Wang, Jian ^a   Zhao, Hong ^a   Kufrin, Dubravka ^a   Palmby, Todd ^a   Dong, Zedong ^a   Russell, Anne Marie ^a   Miksinski, Sarah ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; VISMODEGIB;

ACUTE HEART INFARCTION; ADVANCED CANCER; AGEUSIA; ALOPECIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BLEEDING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUBILITY; DYSGEUSIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPOVOLEMIC SHOCK; INSOMNIA; LUNG EMBOLISM; MENINGISM; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; TOXICITY TESTING; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG APPROVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84877089372     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1956     Document Type: Article

References (21)

1. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J 1997;73, 538-42. (Pubitemid 27448250)
2. Abdulla FR, Feldman SR, Williford PM, Krowchuk D, Kaur M. Tanning and skin cancer. Pediatr Dermatol 2005;22,501-12. (Pubitemid 43951453)
3. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-7.
4. NCCN clinical practice guidelines in oncology: basal cell and squamous cell skin cancers. [Accessed 2012 Feb 21.] Available from: http://www.nccn.org/ professionals/physician-gls/pdf/nmsc.pdf
5. Chinem VP, Miot HA. Epidemiology of basal cell carcinoma. An Braz Dermatol 2011;86:292-305.
6. Cohen B, Weiss G, Yin H. Basal cell carcinoma (BCC) causing spinal cord compression. Dermatol Online J 2000;6:12.
7. Kovarik CL, Stewart D, Barnard JJ. Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol0 2005;52:149-51.
8. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 1990;26:73-7. (Pubitemid 20121854)
9. Ganti AK, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. Cancer Treat Rev 2011;37:440-3.
10. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984;10:1043-60. (Pubitemid 14111165)
11. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PI, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991;24:715-9.
12. Spates ST, Mellette JR, Fitzpatrick J. Metastatic basal cell carcinoma. Dermatol Surg 2003;29:650-2. (Pubitemid 36702454)
13. Johnson R, Rothman A, Xie J, Goodrich L, Bare J, Bonifas J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71. (Pubitemid 26200029)
14. Kimonis V, Goldstein A, Pastakia B, Yang M, Kase R, DiGiovanna J, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Gen 1997;69:299-308. (Pubitemid 27154674)
15. Li Y, Maitah M, Ahmad A, Kong D, Boa B, Sarkar F. Targeting the hedgehog signaling pathway for cancer. Expert Opin Ther Targets 2012;16:49-66.
16. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
17. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genetics 2006;7:841-50. (Pubitemid 44607100)
18. Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang J, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 2012;74:788-96.
19. Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, et al. A single dose mass balance study of the hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Disposition 2011;39:1460-7.
20. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9.
21. Low J. Pediatric oncology subcommittee of the oncologic drugs advisory committee meeting, November 1, 2011. [Accessed 2013 Jul 13.] Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugsAdvisoryCommittee/UCM281987.pdf.